Business
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion
NEW YORK, December 15, 2025--SK Capital Partners, LP ("SK Capital"), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG ("Swixx" or the "Company") to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical
About this update from Hbm Healthcare Investments Ag Temp
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2421,"height":521,"url":"https://media.zenfs.com/en/business-wire.com/7ed5476552ed932744f4ebdb6bcf3098"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o74nc4f6BXJsvlHq_sTi7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7ed5476552ed932744f4ebdb6bcf3098","width":960,"height":207},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/854jhPvSfzqeDgZ36LGvHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7ed5476552ed932744f4ebdb6bcf3098","width":1200,"height":258}},"lazy":false},{"type":"text","content":"NEW YORK, December 15, 2025--(BUSINESS WIRE)--SK Capital Partners, LP ("SK Capital"), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG ("Swixx" or the "Company") to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets.","length":675,"tagName":"p"},{"type":"text","content":"Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specialized investment firm, will also remain as committed shareholders in Swixx.","length":472,"tagName":"p"},{"type":"text","content":"Aaron Davenport, Managing Director at SK Capital, commented, "We are excited to partner with Swixx BioPharma, a company that shares our commitment to improving patient outcomes and advancing healthcare. Our investment underscores confidence in Swixx’s leadership and its ability to deliver sustainable business growth across diverse markets."","length":352,...